This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

AMSAMSAn introduction to antimicrobial stewardshipStewardshipSurveillanceRace against resistanceABSABSABS in practice Educational ResourcesAFSAFSShape the futureAFS in practiceImplementing an AFS programmeDiagnosticsGuidelinesCase studiesAll case studiesDisease AwarenessDisease AwarenessAspergillosisOur CommitmentOur CommitmentOur commitment to anti-infectivesHeritageSustainability
Our work in the community
Support & ResourcesSupport & ResourcesVideosMaterialsOnline LearningOnline LearningHomeINSPIRE To: Change the CourseINSPIRE To: Change the Course Season 2The global threat of carbapenemase-producing enterobacterales (CPE)CPE Epidemiology CPE Factsheet London AMS SeriesNorth West England AMS SeriesInfectious Thinking Podcasts

Information on how to access prescribing information and adverse event reporting can be found at the bottom of the page.

Case studies Examples and key findingsaCase 2: St George’s University Hospital, London1,2
  • 432 patients reviewed over 6 years (October 2010 – September 2016)
  • Clinical interventions: diagnostic and therapeutic advice
  • Results:
    • 82% of cases who received empirical treatment did so unnecessarily, subsequently found to have no evidence of invasive fungal infection 
    • 30% reduction in annual antifungal expenditures
Case 3: Wythenshawe Hospital, Manchester1,3
  • Two 4-month audits in 2014 and 2016 by the AFS team
  • Clinical interventions: education and training, recruitment of AFS champions
  • Results:
    • 90% reduction in inappropriate antifungal treatment initiation
    • 58% reduction in mortality due to invasive candidiasis compared with 2003–2007
    • 49% cost reduction
Case 4: Royal Brompton and Harefield NHS Foundation Trust, London4
  • 178 patients reviewed over 18 months (January 2015–June 2016)
  • Clinical interventions: recommendations that included outpatient or MDT reviews, diagnostic investigations and treatment adjustments
  • Results:
    • Antifungal use decreased significantly (p=0.017)
    • Improved TDM may have reduced the need for second-line therapies
    • £130,000 monthly saving in antifungal drugs, 45% cost reduction
Case 5: Addenbrookes Hospital, Cambridge5
  • 173 patients reviewed on 294 occasions over 12 months (July 2013–July 2014)
  • Clinical interventions: diagnostic and therapeutic advice
  • Results:
    • 72% of reviews resulted in advice given, which was generally accepted
    • Increase in laboratory tests
    • £180,000 annual saving in antifungal drugs; 10% cost reduction
Case 6: University Hospital of Wales, Cardiff1,6,7
  • 5-year review of 549 high-risk haematology and stem-cell transplant recipients
  • Clinical interventions: diagnostic testing
  • Results:
    • Twice-weekly PCR screening and antigen testing had 98% sensitivity and 99.6% negative predictive value when used together, and 95% specificity for accurate diagnosis of aspergillosis
    • No reported excess in morbidity or mortality
    • £124,572 reduction in overall antifungal expenditure in the initial 6-month test period

The case studies featured on this page offer a glimpse into the impact a successful AFS programme can make. To read about these cases in full, download the booklet.

a. This content provides an overview of different AFS programmes implemented in the UK, based on published data. This is not meant to be a comparative analysis, and the way the information is presented may differ between programmes.

ABS, antibacterial stewardship; AFS, antifungal stewardship; AMS, antimicrobial stewardship; MDT, multidisciplinary team; NHS, National Health Service; PCR, polymerase chain reaction.

Prescribing Information:

Click here for CRESEMBA® (isavuconazole) prescribing information

References:

Talento AF et al. J Fungi 2021;7:801. https://doi.org/10.3390/jof7100801.Whitney L et al. J Antimicrob Chemother 2019;74(1):234–241.Rautemaa-Richardson R et al. J Antimicrob Chemother 2018;73(12):3488–3495.Nwankwo L et al. Antimicrob Agents Chemother 2018;62(10).Micallef C et al. J Antimicrob Chemother 2015;70(6):1908–1911.Barnes RA et al. J Clin Pathol 2009;62:64–69.Barnes RA et al. J Infect 2013;67(3):206–214.
PP-CRB-GBR-1640. August 2022.
Shape the future (AFS)DownloadLoading Delve further into antifungal stewardship case studies

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​